Supporting the Rationale for the Use of Dapagliflozin as an Add-on to Poorly Controlled Patients on Saxagliptin and Metformin Zachary Bloomgarden, MD Clinical Professor Division of Endocrinolog Icahan School of Medicine New York, New York Julio Rosenstock, MD Clinical Professor University of Texas Southwestern Medical School Dallas, TX American Diabetes Association 2014, Meeting

Conclusions Newer anti-diabetes agents have come to be more likely prescribed by practitioners as they grapple for solutions to the growing diabetes epidemic. Leading researchers agree that metformin should be the beginning choice for all type two patients, but after that the field is wide open Many prescribers try to mix and match because of formulary guidelines and cost consciousness. Adding on supposedly synergistic medications often leave the patient with less than meaningful response than is expected The Use of SGLT-2 Inhibitors Blockers with DPP-4 Inhibitors has been shown to have a positive effect on A1c, Weight Loss, and Hypertension